Primary carE PPi dEprescRibing Trial

Exclusion Criteria

• •Patients on short-term (\<12 weeks) PPI therapy.
• •Patients not on chronic PPI use (less than daily intake)
• •Patients with established long-term indication such as the presence of a grade C, D oesophagitis, a peptic ulcer, Barrett's oesophagus or Zollinger-Ellison syndrome.
• •Patients with chronic use of Gaviscon® or similar drugs based on magaldrate such as Riopan® and Gastricalm® (i.e. more than once a week for the last 2 months).
• •Patients with chronic use of NSAIDs (i.e. two or more weekly doses).
• •Patients with a history of gastric or oesophageal surgery.
• •Patients with a major oesophageal disease such as achalasia, oesophageal spasm, or oesophageal involvement in systemic disease such as scleroderma or dermatomyositis.
• •Patients with drug abuse and/or alcohol abuse
• •Women who are pregnant or lactating
• •Patients not able to understand or be compliant with the study.